Compare DWSN & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DWSN | EQ |
|---|---|---|
| Founded | 1952 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4M | 64.5M |
| IPO Year | 1995 | 2018 |
| Metric | DWSN | EQ |
|---|---|---|
| Price | $3.46 | $1.79 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 78.2K | ★ 483.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.11 | 39.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $145,773,000.00 | $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 13.89 |
| 52 Week Low | $1.08 | $0.29 |
| 52 Week High | $5.54 | $2.35 |
| Indicator | DWSN | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 70.31 | 62.24 |
| Support Level | $1.34 | $1.33 |
| Resistance Level | $5.54 | $2.30 |
| Average True Range (ATR) | 0.29 | 0.14 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 83.69 | 64.58 |
Dawson Geophysical Co is a provider of onshore seismic data acquisition services with operations throughout the continental United States and Canada. The company acquires and processes 2 D, 3 D, and multi-component seismic data for clients, ranging from oil and gas companies to independent oil and gas operators for use in the onshore drilling and production of oil and natural gas as well as provides multi-client data libraries. It operates through a single segment being Contract seismic data acquisition and processing services. In addition, the company provides multi-component seismic data surveys which involve the recording of alternative seismic waves. Geographically, it generates maximum revenue from the United States.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.